AR003959A1 - Reactivo para preparar un grupo biologicamente activo conectado a un grupo hidrazona estable, conjunto de elementos para preparar un agente radio-farmaceutico y compuesto de hidrazona estable. - Google Patents

Reactivo para preparar un grupo biologicamente activo conectado a un grupo hidrazona estable, conjunto de elementos para preparar un agente radio-farmaceutico y compuesto de hidrazona estable.

Info

Publication number
AR003959A1
AR003959A1 ARP960103028A AR10302896A AR003959A1 AR 003959 A1 AR003959 A1 AR 003959A1 AR P960103028 A ARP960103028 A AR P960103028A AR 10302896 A AR10302896 A AR 10302896A AR 003959 A1 AR003959 A1 AR 003959A1
Authority
AR
Argentina
Prior art keywords
prepare
stable hydrazone
elements
biologically active
reagent
Prior art date
Application number
ARP960103028A
Other languages
English (en)
Spanish (es)
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of AR003959A1 publication Critical patent/AR003959A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP960103028A 1995-06-07 1996-06-07 Reactivo para preparar un grupo biologicamente activo conectado a un grupo hidrazona estable, conjunto de elementos para preparar un agente radio-farmaceutico y compuesto de hidrazona estable. AR003959A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/476,296 US5750088A (en) 1993-03-30 1995-06-07 Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals

Publications (1)

Publication Number Publication Date
AR003959A1 true AR003959A1 (es) 1998-09-30

Family

ID=23891282

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103028A AR003959A1 (es) 1995-06-07 1996-06-07 Reactivo para preparar un grupo biologicamente activo conectado a un grupo hidrazona estable, conjunto de elementos para preparar un agente radio-farmaceutico y compuesto de hidrazona estable.

Country Status (29)

Country Link
US (2) US5750088A (2)
EP (1) EP0832068B1 (2)
JP (1) JPH11507364A (2)
KR (1) KR19990022573A (2)
CN (1) CN1192733A (2)
AR (1) AR003959A1 (2)
AT (1) ATE233241T1 (2)
AU (1) AU718683B2 (2)
BR (1) BR9609003A (2)
CA (1) CA2222183A1 (2)
CZ (1) CZ380197A3 (2)
DE (1) DE69626392T2 (2)
EA (1) EA000742B1 (2)
EE (1) EE9700313A (2)
ES (1) ES2193245T3 (2)
HR (1) HRP960250A2 (2)
HU (1) HUP9901469A3 (2)
IL (1) IL118468A0 (2)
LT (1) LT4380B (2)
LV (1) LV12044B (2)
MX (1) MX9709126A (2)
MY (1) MY133974A (2)
NO (1) NO975678L (2)
NZ (1) NZ310799A (2)
PL (1) PL323995A1 (2)
SI (1) SI9620076B (2)
SK (1) SK163497A3 (2)
WO (1) WO1996040637A1 (2)
ZA (1) ZA964854B (2)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0888130B1 (en) * 1996-03-13 2003-07-02 Bristol-Myers Squibb Pharma Company New ternary radiopharmaceutical complexes
US20030124053A1 (en) * 1996-10-07 2003-07-03 Barrett John Andrew Radiopharmaceuticals for imaging infection and inflammation
KR20000048922A (ko) * 1996-10-07 2000-07-25 블레어 큐. 퍼거슨 감염 및 염증의 영상화용 방사성 약제
US6416733B1 (en) 1996-10-07 2002-07-09 Bristol-Myers Squibb Pharma Company Radiopharmaceuticals for imaging infection and inflammation
US6403054B1 (en) * 1997-05-28 2002-06-11 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) * 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
WO1999051628A1 (en) * 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer
HRP990317A2 (en) * 1998-10-13 2000-06-30 Du Pont Pharm Co A process for the preparation of a thrombus imaging agent
EP1140864A2 (en) * 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
CA2727746A1 (en) 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) * 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6808698B1 (en) 1999-03-26 2004-10-26 Bristol-Myers Squibb Pharma Company Method for localization of blood clots
BR0010517A (pt) * 1999-03-26 2002-01-08 Du Pont Pharm Co Métodos de formação de imagem de um trombo, de um êmbolo pulmonar, de um trombo arterial e de um trombo coronariano
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US20030220646A1 (en) * 2002-05-23 2003-11-27 Thelen Sarah L. Method and apparatus for reducing femoral fractures
US6534038B2 (en) * 2000-04-07 2003-03-18 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
AU2002230576A1 (en) * 2000-11-03 2002-05-15 Bristol-Myers Squibb Pharma Company Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
GB0031592D0 (en) * 2000-12-28 2001-02-07 Nycomed Amersham Plc Stabilised radiopharmaceutical compositions
MXPA04001113A (es) * 2001-08-08 2004-07-08 Bristol Myers Squibb Pharma Co Formacion de imagenes simultaneas de perfusion cardiaca y agente formador de imagenes dirigido al receptor de vitronectina.
US6838074B2 (en) 2001-08-08 2005-01-04 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7317104B2 (en) 2003-06-13 2008-01-08 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US7319149B2 (en) * 2003-06-13 2008-01-15 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
CA2526556C (en) * 2003-07-24 2012-09-25 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for their preparation
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
WO2007005491A1 (en) * 2005-06-30 2007-01-11 Bristol-Myers Squibb Pharma Company Hydrazide conjugates as imaging agents
WO2007046411A1 (ja) * 2005-10-19 2007-04-26 Dainippon Sumitomo Pharma Co., Ltd. イソキサゾール化合物の安定化方法
AU2006327300A1 (en) * 2005-12-20 2007-06-28 Astrazeneca Ab Substituted Cinnoline derivatives as GABAa-receptor modulators and method for their synthesis
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
JP5571387B2 (ja) 2007-01-11 2014-08-13 クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド 癌の治療のための化合物および方法
AR067028A1 (es) * 2007-06-19 2009-09-30 Astrazeneca Ab Compuestos y usos de los mismos 849
CA2710039C (en) * 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2318406B1 (en) * 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
FR2940652B1 (fr) * 2008-12-29 2011-02-11 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
WO2010076525A1 (fr) 2008-12-29 2010-07-08 Sanofi-Aventis Dérivés de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur préparation et leur application en thérapeutique
FR2949468B1 (fr) * 2009-08-28 2011-09-30 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
KR20110099786A (ko) 2008-12-29 2011-09-08 사노피 ２-피리딘-２-일-피라졸-３（２ｈ）-온의 유도체, 그의 제조법 및 ｈｉｆ 활성화제로서의 치료 용도
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
FR2967671A1 (fr) * 2010-11-24 2012-05-25 Pf Medicament Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
CN110818624B (zh) * 2019-11-22 2022-11-22 华东理工大学 吡啶季铵盐腙类化合物及制备方法与在抗菌或香料缓释中的应用
CN112999369B (zh) * 2021-03-03 2022-02-25 江苏元本生物科技有限公司 一种her2亲合体放射性核素标记物组合物及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427646A (en) 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
CA1300608C (en) * 1985-05-10 1992-05-12 Edward A. Deutsch 99 mtc (iii) myocardial imaging agents which are non-reducable in vivo
GB8624272D0 (en) * 1986-10-09 1986-11-12 Amersham Int Plc Cationic complexes of tc-99m
US5217705A (en) 1987-09-25 1993-06-08 Neorx Corporation Method of diagnosing blood clots using fibrin-binding proteins
AU639409B2 (en) 1987-12-10 1993-07-29 La Jolla Cancer Research Foundation Conformationally stabilized cell adhesion peptides
JPH07110869B2 (ja) * 1988-03-09 1995-11-29 セ・イ・エス・ビオ・アンテルナシヨナル 放射性医薬品として使用できる９９ｍＴｃ、１８６Ｒｅまたは１８８Ｒｅの窒化物錯体の製造方法
GB8808414D0 (en) * 1988-04-11 1988-05-11 Amersham Int Plc Ligands & cationic complexes thereof with technetium-99m
EP0412115A4 (en) 1988-04-29 1991-11-13 New England Deaconess Hospital Corporation Hybrid peptides and methods of their use
US5002754A (en) * 1988-06-15 1991-03-26 University Of Cincinnati Technetium (III/II) imaging agents
HUT55799A (en) 1988-09-29 1991-06-28 Biogen Inc Process for producing hirudine-like peptides
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5270030A (en) 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
GB8902362D0 (en) * 1989-02-03 1989-03-22 Amersham Int Plc Cationic complexes of technetium-99m
IL93432A (en) * 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules and such conjugates labelled with metal ions
US5206370A (en) * 1989-02-24 1993-04-27 Johnson Matthey, Inc. Certain pyridyl hydrazines and hydrazides useful for protein labeling
US4957728A (en) * 1989-05-19 1990-09-18 University Of Cincinnati Kit for preparing Tc (III)-99m myocardial imaging agents that are effective in humans
US4917879A (en) * 1989-05-19 1990-04-17 University Of Cincinnati 99MTC(III) myocardial imaging agents that are effective in humans
GB8914020D0 (en) 1989-06-19 1989-08-09 Antisoma Ltd Synthetic peptides for use in thrombus detection
EP0410537A1 (en) 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
GB8919488D0 (en) * 1989-08-29 1989-10-11 Amersham Int Plc New cores for technetium radiopharmaceuticals
ZA907743B (en) 1989-10-03 1991-07-31 Merrell Dow Pharma Radiolabeled anticoagulant peptides
US5086069A (en) 1990-02-05 1992-02-04 Rorer Pharmaceutical Corporation Anti-thrombotic peptide and pseudopeptide derivatives
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
FR2664166A1 (fr) * 1990-07-04 1992-01-10 Cis Bio Int Procede de preparation de complexes nitruro de metaux de transition utilisables comme produits radiopharmaceutiques ou pour la synthese de nouveaux produits radiopharmaceutiques.
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
EP0510132B1 (en) * 1990-09-28 1997-05-14 Neorx Corporation Polymeric carriers for release of covalently linked agents
US5112594A (en) * 1991-04-04 1992-05-12 Mallinckrodt Medical, Inc. Kit for preparing a technetium-99m myocardial imaging agent
JP2774378B2 (ja) 1991-02-08 1998-07-09 ダイアテク，インコーポレイテッド 映像用テクネチウム−９９ｍ標識化ポリペプチド
FR2679452B1 (fr) * 1991-07-22 1993-11-12 Cis Bio International Produit radiopharmaceutique ayant notamment un tropisme cerebral, comportant un complexe nitruro d'un metal de transition, et son procede de preparation.
US5362852A (en) * 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
ATE329624T1 (de) 1992-05-21 2006-07-15 Diatide Inc Technetium-99m markierte peptide zur bilderzeugung von thrombus
GB2268494B (en) 1992-07-08 1996-08-21 Kenneth Francis Prendergast Imaging compositions
FR2698272B1 (fr) * 1992-11-20 1994-12-30 Cis Bio Int Procédé de marquage cellulaire au moyen de complexes nitruro-bis (dithiocarbamato)Tc-99m et trousse pour la mise en Óoeuvre de ce procédé.
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders

Also Published As

Publication number Publication date
SI9620076A (sl) 1998-08-31
EP0832068A1 (en) 1998-04-01
CN1192733A (zh) 1998-09-09
BR9609003A (pt) 1999-12-14
EE9700313A (et) 1998-06-15
NO975678D0 (no) 1997-12-05
HUP9901469A3 (en) 2000-02-28
LT4380B (lt) 1998-09-25
HUP9901469A2 (hu) 1999-08-30
LV12044B (en) 1998-09-20
CA2222183A1 (en) 1996-12-19
SI9620076B (sl) 2000-02-29
AU718683B2 (en) 2000-04-20
NO975678L (no) 1998-02-06
MX9709126A (es) 1998-03-31
NZ310799A (en) 2000-01-28
EA000742B1 (ru) 2000-02-28
WO1996040637A1 (en) 1996-12-19
JPH11507364A (ja) 1999-06-29
DE69626392T2 (de) 2004-04-22
SK163497A3 (en) 1998-10-07
DE69626392D1 (de) 2003-04-03
HRP960250A2 (en) 1997-12-31
US5750088A (en) 1998-05-12
EP0832068B1 (en) 2003-02-26
LT97191A (en) 1998-04-27
CZ380197A3 (cs) 1998-07-15
LV12044A (lv) 1998-05-20
ATE233241T1 (de) 2003-03-15
MY133974A (en) 2007-11-30
US6015904A (en) 2000-01-18
ES2193245T3 (es) 2003-11-01
ZA964854B (en) 1997-12-08
PL323995A1 (en) 1998-04-27
AU6166196A (en) 1996-12-30
KR19990022573A (ko) 1999-03-25
EA199800025A1 (ru) 1998-06-25
IL118468A0 (en) 1996-09-12

Similar Documents

Publication Publication Date Title
AR003959A1 (es) Reactivo para preparar un grupo biologicamente activo conectado a un grupo hidrazona estable, conjunto de elementos para preparar un agente radio-farmaceutico y compuesto de hidrazona estable.
ES2179196T3 (es) Complejos radiofarmacos ternarios.
DK0630265T3 (da) Technetium-99m mærkede peptider til afbildning af inflammation
DK0684843T3 (da) Technetium-99m-mærkede peptider til diagnostisk billeddannelse af inflammation
CY1106860T1 (el) Δομες χρωστικων ευαισθητες σε οξεα και διασπωμενες ενζυμικα για τη διαγνωστικη με ακτινοβολια εγγυς υπερυθρου και για τη θεραπεια
BR9607933A (pt) Reagente para preparar um radiofarmacêutico agente de formação de imagem cintigráfica e radioterapêutico complexo composição kit para preparar uma preparação radiofarmacêutica processo para rotular um reagente para formar uma imagem de um sítio e para fazer um reagente composição de matéria e uso do reagente
UA32577C2 (uk) Радіомічена сполука для утворення зображення тромбів при радіонуклідній діагностиці, радіофармацевтичний препарат та радіофармацевтична композиція на їх основі та комплект для приготування радіофармацевтичних препаратів
ES8404857A1 (es) Un procedimiento para preparar un anticuerpo monoclonal para un antigeno asociado a un tumor.
ATE28569T1 (de) Zusammensetzung, die einen radiomarkierten antikoerper enthaelt, ausruestung zu ihrer herstellung und ausruestung zur krebs- oder tumorbestimmung, die diese zusammensetzung enthaelt.
HUP0400253A2 (hu) Szilárd fázisú nukleofil fluorozás
ES2121792T3 (es) Anticuerpo monoclonal.
PT1381611E (pt) Analogos de ftalocianina substituidas com metal sem centro de simetria sua preparacao e uso em terapia fotodinamica e em diagnostico in vivo
DE69912983D1 (de) Wassermischbare pharmazeutische zusammensetzungen enthaltend paclitaxel
Washburn et al. DL-[Carboxyl-11C] tryptophan, a potential agent for pancreatic imaging; production and preclinical investigations
DE69841322D1 (de) Hepatitis c rezeptorprotein cd81
BR0314716A (pt) Anticorpos de subunidade alfa de lfa-1 e métodos de uso
Nguyen et al. Efficacy of nimotuzumab (hR3) conjugated with 131I or 90Y in laryngeal carcinoma xenograft mouse model
ES2165971T3 (es) Suspensiones de liposomas como agentes de contraste para la imagineria de la sangre.
Naqvi et al. Radiosynthesis and preclinical studies of 177Lu-labeled sulfadiazine: a possible theranostic agent for deep-seated bacterial infection
DK0788377T3 (da) Radiomærkede glucaner
ES2032309T3 (es) Compuestos de formazano complejo con cobre, procedimiento para su preparacion y su aplicacion como colorantes.
WATANABE et al. Disposition of fractionated 3H-heparin in rats
DE60206599D1 (de) Biotin-derivate und ihre konjugaten mit chelatierungsmitteln
BR9913627A (pt) Uso de um derivado de antraciclina para o tratamento de um tumor no fìgado
ES2093135T3 (es) Anticuerpos monoclonales contra el complejo plasmina-antiplasmina, procedimiento para su preparacion asi como su utilizacion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal